All In Biotech

Drug Trial Radar · NCT01309542

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

A 10 Month Open-Label Evaluation Of The Long-Term Safety Of DVS-233 SR In Outpatients With Major Depressive Disorder.

Last checked: Nov 19, 2026Latest source record: Apr 26, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,403

Actual

Start

Aug 2003

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluated the long-term safety of Desvenlafaxine Succinate (DVS) Slow Release (SR) during open-label treatment in adult outpatients who had a primary diagnosis of major depressive disorder (MDD). The study also evaluated the long-term response of subjects receiving DVS SR for clinical global evaluation, functionality, general well-being, pain, and absence of depressive symptoms (remission).

Conditions

  • Major Depressive Disorder

Interventions

  • Desvenlafaxine SuccinateDrug

    Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number (%) of Subjects Reporting Adverse Events during TreatmentTime frame: 10 months
  2. Number (%) of Subjects With Changes in Vital Signs (Blood Pressure, Pulse Rate, Weight) of Potential Clinical ImportanceTime frame: 10 months
  3. Number (%) of Subjects With Laboratory Test Results (Hematology, Blood Chemistry, Lipid Profile, Urinalysis) of Potential Clinical ImportanceTime frame: 10 months
  4. Number (%) of Subjects With Electrocardiogram Results (Heart Rate, QTc interval) of Potential Clinical ImportanceTime frame: 10 months

Locations

117 sites in 11 countries. Site status is shown where the registry gives one.

  • Birmingham Research Group Inc.

    Birmingham, Alabama

  • Pivotal Research Centers 13128 North 94th Drive, Suite 200

    Mesa, Arizona

  • Pivotal Research

    Peoria, Arizona

  • Southwestern Research, Inc.

    Beverly Hills, California

  • Feighner Research Institute

    Chula Vista, California

  • California Clinical Trials Medical Group, Inc.

    Glendale, California

  • Pharmacology Research Institute

    Newport Beach, California

  • Pacific Clinical Research

    Orange, California

  • UCSD Department of Psychiatry Psychopharmacology Research

    San Diego, California

  • Southwestern Research, Inc.

    Tustin, California

  • Alpine Clinical Research Center, Inc.

    Boulder, Colorado

  • Feiger Health Research Center

    Lakewood, Colorado

  • University of Connecticut Health Center

    Farmington, Connecticut

  • New Britain General Hospital

    New Britain, Connecticut

  • The George Washington University Medical Center

    Washington D.C., District of Columbia

  • CORE Research, Inc.1006 NW 14

    Leesburg, Florida

  • Lifestream Behavioral Center

    Leesburg, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Miami Research Associates, Inc.

    South Miami, Florida

  • Comprehensive NeuroScience, Inc.

    St. Petersburg, Florida

  • Kolin Research Group 1065 West Morse Blvd. Suite 202

    Winter Park, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Atlanta Institute of Medicine & Research

    Marietta, Georgia

  • Carman Research

    Smyrna, Georgia

  • Radiant Research - Chicago

    Chicago, Illinois

  • Ingenium Clinical Research

    Libertyville, Illinois

  • Capital Clinical Research Associates, LLP

    Rockville, Maryland

  • DuPont Clinical Research, Inc.

    Rockville, Maryland

  • Institute for Health Studies

    Okemos, Michigan

  • Creighton University

    Omaha, Nebraska

  • Center for Emotional Fitness

    Cherry Hill, New Jersey

  • CRI Worldwide, LLC

    Clementon, New Jersey

  • Social Psychiatry Research Institute

    New York, New York

  • The Medical Research Network

    New York, New York

  • Anxiety & Depression Clinic

    The Bronx, New York

  • Piedmont Neuropsychiatry

    Charlotte, North Carolina

  • Hartford Research Group

    Cincinnati, Ohio

  • Midwest Clinical Research Center, LLC

    Dayton, Ohio

  • Neurology & Neuroscience Center of Ohio

    Toledo, Ohio

  • IPS Research Company

    Oklahoma City, Oklahoma

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.